Article Index

How to Protect Your Biotech Profits from This Legal Limbo

biotech profits

Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.

Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long - 24 to 48 weeks - and arduous.

Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.

Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.

So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.

There's just one big, expensive problem...

Hot Tech Startup Raises $12 Million to Transform Healthcare

tech startup

A hot new tech startup, AiCure, is trying to close the healthcare industry’s $378 billion annual gap.

Its goal involves the use of an app and artificial intelligence.

As well as users' diligence in taking selfies...

Ekso Bionics – 33 Million Strides Taken to Corner a $2.1 Billion Market


No company captures the imagination the way Ekso Bionics Holdings Inc. (OTCBB: EKSO) does.

The tiny exoskeleton maker just reported earnings and, as you might expect, there's broad-based growth in every metric that matters.

But there's something the media isn't covering.

Ironically, it's the single most important factor in what I believe will ultimately be an exceptionally bright future for the company and savvy investors alike.

Here's why there's more upside for Ekso than any analyst will tell you.

Biotech Investing Buff Just Made $1.1 Billion Profit in 8 Months – Here's How

Biotech Investing

With a net worth of $12.6 billion, Patrick Soon-Shiong, MD, is the world's richest doctor, the richest American in the healthcare industry, and the 96th-richest person on the planet in 2015 according to Forbes.

And just in August, the 63-year-old became $1.1 billion richer -- from a move he'd made only eight months prior, according to Bloomberg...

Here's Soon-Shiong's story - plus five ways you can cash in with biotech profits of your own...

A Biotech Stock to Buy with "Nearly Limitless" Profit Potential


Today, we're recommending a biotech stock to buy that Money Morning Biotech Investing Specialist Ernie Tremblay says has a "nearly limitless" profit potential.

It's a medical device company with a revolutionary product that helps restore vision to people suffering from blindness.

Here's the revolutionary technology behind this biotech stock to buy...

This Cannabis Biotech Leader Helped Us Beat the Market by More Than 620%


Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.

Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.

And if you missed this stock last year - no worries. We'll start you now as it continues its run - a run that took off while "popular" medical marijuana stocks cratered.

Here's how we'll do it...

Navigating the Shoals of an Overvalued Market


Stocks have struggled to rally in recent weeks, but that hasn't stopped the IPO market from offering investors the chance to leave reason behind.

Last week, two particular deals demonstrated that while the overall market is expensive, pockets of it are undeniably in a bubble.

Here's what you should know about the IPOs and the week...

Here's what you should know about the IPOs and the week...

"21st Century Cures" Could Revolutionize Biotech

Medicine Pills Stacked Like Increasing Graph on Newly Designed U.S. One Hundred Dollar Bills.

No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

But new regulations on the table could change everything for biotech investors and critically ill patients...

Biotech Investing for Beginners: Your 7-Step Guide

Biotech news

Biotech investing can be tricky. The industry is complicated, and the stocks are volatile.

But the profit payoff can be life-changing.

That's why we've created the "Biotech Investing for Beginners Guide" with Money Morning's Biotech Investing Specialist Ernie Tremblay.

That's because many of the metrics we use to evaluate other stocks - like P/E ratio, profit margin, earnings per share - don't always apply to biotech stocks.

Here's Tremblay's step-by-step guide to investing in biotech stocks...

Two Divergent Northbound Stocks to Buy Right Now


I want to spend today talking to you about two stocks that we've repeatedly recommended to Private Briefing readers.

Both stocks made bullish headlines last week.

One of the stocks is a winner - a big winner, in fact. And the other has been a loser - so far.

But we're predicting it will be a big winner, too - a huge winner.

And last week's developments strengthened our case...

3 of the Best Biotech Stocks to Buy Today

best biotech stocks

If you're looking for the best biotech stocks on the market, you've come to the right place.

Our biotech specialists aren't considered to be among the best... they are the best.

And they picked three of the best biotech stocks to profit from today...

5 Pharmaceutical Stocks to Avoid

pharmaceutical stocks

Pharmaceutical stocks can plummet for myriad reasons: loss of funding, lawsuits, poor clinical trials.

It's a risky sector to get yourself involved in - one with big rewards. But, where there are big rewards, there are also big losses.

We took a look at five pharmaceutical stocks you should avoid...

Six Pharmaceutical Stocks That Outperformed the Rest in 2014

pharmaceutical stocks

Pharmaceutical stocks soar when their companies receive FDA approval. The key to investing in the pharmaceutical sector is research: you've got to know when, how and if the company you like will profit.

That's why we've compiled a list of the leading pharmaceutical stocks around.

Have a look at these drug companies yielding impressive gains while they treat diseases...

One Stock That Will Profit from a New, Breakthrough Medical Direction

Medical doctor male

Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything. It treats. It manages. It postpones the inevitable.

But return a patient to normal, optimal health?


So when an innovation comes along that can effect a complete and permanent remission of disease or restore damaged organs to a pristine state, it should cause your keenest investing instincts to perk up and pay attention...

This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough

new Alzheimer’s drug

Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.

But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.

In other words, there is a way to both fight Alzheimer’s and supercharge your portfolio – today…